Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, ...
We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...
It's been a pretty great week for Travere Therapeutics, Inc. ( NASDAQ:TVTX ) shareholders, with its shares surging ...
In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...
Fintel reports that on November 4, 2025, Piper Sandler maintained coverage of Travere Therapeutics (NasdaqGM:TVTX) with a ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported third-quarter earnings of $25.7 million. On a per-share basis, the San Diego-based company said it had net ...
Travere’s financial performance in Q3 2025 exceeded expectations, with total revenue of $164.9 million compared to the forecast of $105.57 million. The company reported a net income of $25.7 million, ...
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to a loss of $0.7 per share a year ago ...
Travere Therapeutics Inc. reported a strong financial performance for the third quarter of 2025, with earnings per share (EPS) of $0.59, significantly surpassing the forecasted loss of $0.29. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results